Shattuck Labs(US:STTK) Newsfilterยท2025-03-27 11:00Core Insights - Shattuck Labs, Inc. is advancing its lead product candidate SL-325, a potentially first-in-class DR3 blocking antibody, towards Phase 1 clinical trials with an IND filing expected in Q3 2025 [1][5][9] Financial Overview - As of December 31, 2024, Shattuck Labs reported a cash balance of approximately $73.0 million, which is expected to fund operations into 2027 [1][8] - Research and Development (R&D) expenses for Q4 2024 were $15.4 million, slightly up from $15.2 million in Q4 2023, while total R&D expenses for the year decreased to $67.2 million from $74.3 million in 2023 [12][17] - General and Administrative (G&A) expenses for Q4 2024 were $4.2 million, down from $4.4 million in Q4 2023, with total G&A expenses for the year at $19.1 million compared to $19.3 million in 2023 [12][17] - The net loss for Q4 2024 was $18.7 million, or $0.37 per share, compared to a net loss of $17.7 million, or $0.41 per share, in Q4 2023 [12][17] Product Development - SL-325 has demonstrated a favorable safety profile in preclinical studies, with no infusion-related reactions and full receptor occupancy at doses of 1 mg/kg or greater [5][9] - The Phase 1 clinical trial will assess safety, tolerability, and pharmacokinetics, with complete enrollment expected by Q2 2026 [5][9] - Shattuck Labs is also developing multiple preclinical DR3-based bispecific antibodies aimed at treating IBD, with plans to nominate a lead bispecific candidate in 2025 [5][9] Recent Developments - The company presented preclinical data for SL-325 at the 20th Congress of ECCO, highlighting its potential for achieving best-in-class clinical remission rates for IBD patients [1][2] - The decision to terminate the SL-172154 program in 2024 was made to focus resources on the development of SL-325 [2]